MX336607B - Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa. - Google Patents

Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.

Info

Publication number
MX336607B
MX336607B MX2012014836A MX2012014836A MX336607B MX 336607 B MX336607 B MX 336607B MX 2012014836 A MX2012014836 A MX 2012014836A MX 2012014836 A MX2012014836 A MX 2012014836A MX 336607 B MX336607 B MX 336607B
Authority
MX
Mexico
Prior art keywords
xanthine
dosage forms
release dosage
modified release
oxidase inhibitors
Prior art date
Application number
MX2012014836A
Other languages
English (en)
Other versions
MX2012014836A (es
Inventor
Rajneesh Taneja
Majid Vakilynejad
Vijay Gupte
Original Assignee
Takeda Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45328897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX336607(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Usa Inc filed Critical Takeda Pharmaceuticals Usa Inc
Publication of MX2012014836A publication Critical patent/MX2012014836A/es
Publication of MX336607B publication Critical patent/MX336607B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de libración modificada que comprende gránulos de febuxostat de liberación inmediata en una cantidad que fluctúa de aproximadamente 20% hasta aproximadamente 40% (p/p) del peso de la composición total y los gránulos de febuxostat de libración retardada que tienen una solubilidad en niveles de pH mayores o iguales a 6.8 en una cantidad que fluctúa de aproximadamente 60% hasta aproximadamente 80% f(p/p) del peso total, en donde los gránulos de liberación inmediata, comprende: (a) un núcleo inerte en una cantidad que fluctúa de aproximadamente 50% hasta aproximadamente 55% (p/p) del peso del gránulo de libración inmediata, y (b) una capa de libración inmediata que encapsula el núcleo inerte que comprende una mezcla de febuxostat e hidroxipropil metilcelulosa en una cantidad que fluctúa de aproximadamente 45% hasta aproximadamente 50% (p/p) del peso del gránulo de libración inmediata, en donde la proporción de febuxostat a hidroxipropil metilcelulosa fluctúa de aproximadamente 1.5 hasta aproximadamente 3; y en donde los gránulos de liberación retardada comprenden (a) un núcleo inerte en una cantidad que fluctúa aproximadamente 40.5% hasta aproximadamente 43% (p/p) del peso de gránulo de liberación retardada, (b) una capa de liberación inmediata que encapsula el núcleo inerte que comprende una mezcla de febuxostat e hidroxipropil metilcelulosa en una cantidad que fluctúa de aproximadamente 35% hasta aproximadamente 40$ (p/p) del peso del gránulo de liberación retardada, en donde la proporción de fubuxostat a hidroxipropil metilcelulosa fluctúa de aproximadamente 1.5 hasta aproximadamente 3, (c) una capa de polímero entérico de liberación retardada que encapsula la capa de liberación inmediata lque comprende un polímero entérico de liberación retardada en una cantidad que fluctúa de aproximadamente 17% hasta aproximadamente 20% (p/p) del gránulo de liberación retardada, el polímero entérico de liberación retardada que comprenden una mezcla del copolímero de ácido metacrílico tipo A y el copolímero de ácido metacrílico tipo B en una proporción que fluctúa de aproximadamente 0.1 hasta aproximadamente 0.5, y (d) un plastificante en una cantidad que fluctúa de aproximadamente 1% hasta aproximadamente 3% (p/p) del peso del gránulo de libración retardada-controlada, en donde el plastificante comprende citrato de trietilo.
MX2012014836A 2010-06-16 2011-06-15 Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa. MX336607B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35516410P 2010-06-16 2010-06-16
PCT/US2011/040418 WO2011159745A1 (en) 2010-06-16 2011-06-15 Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

Publications (2)

Publication Number Publication Date
MX2012014836A MX2012014836A (es) 2013-05-01
MX336607B true MX336607B (es) 2016-01-25

Family

ID=45328897

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016002326A MX361138B (es) 2010-06-16 2011-06-15 Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.
MX2012014836A MX336607B (es) 2010-06-16 2011-06-15 Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016002326A MX361138B (es) 2010-06-16 2011-06-15 Formas novedosas de dosificacion de liberacion modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa.

Country Status (25)

Country Link
US (2) US9248119B2 (es)
EP (1) EP2582812B1 (es)
JP (2) JP5865904B2 (es)
KR (1) KR101872189B1 (es)
CN (1) CN103210084B (es)
AU (2) AU2011268445B9 (es)
BR (1) BR112012032033A2 (es)
CA (1) CA2801930A1 (es)
CL (1) CL2012003548A1 (es)
CO (1) CO6650415A2 (es)
EC (1) ECSP13012394A (es)
ES (1) ES2669184T3 (es)
HK (1) HK1187371A1 (es)
IL (2) IL223455B (es)
JO (1) JO3450B1 (es)
MX (2) MX361138B (es)
MY (1) MY167126A (es)
NZ (1) NZ604646A (es)
PE (2) PE20130574A1 (es)
RU (1) RU2602188C2 (es)
SG (1) SG186301A1 (es)
TW (1) TW201202249A (es)
UA (1) UA112632C2 (es)
WO (1) WO2011159745A1 (es)
ZA (1) ZA201209386B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR081935A1 (es) * 2010-06-16 2012-10-31 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada
UY33468A (es) * 2010-06-25 2012-01-31 Teijin Pharma Ltd Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal
NZ605562A (en) * 2010-07-09 2013-11-29 Teijin Pharma Ltd Deuterated benzylbenzene derivatives and methods of use
WO2012153313A1 (en) * 2011-05-11 2012-11-15 Ranbaxy Laboratories Limited Pharmaceutical composition of febuxostat
WO2012172461A1 (en) * 2011-06-13 2012-12-20 Ranbaxy Laboratories Limited Pharmaceutical compositions of febuxostat
MX2014008484A (es) * 2012-01-27 2014-10-14 Teijin Pharma Ltd Agente terapeutico para la diabetes mellitus.
WO2014009817A1 (en) * 2012-07-12 2014-01-16 Alembic Pharmaceuticals Limited Pharmaceutical composition of febuxostat
CN102973530B (zh) * 2012-12-14 2016-08-03 贵州信邦制药股份有限公司 一种非布索坦双层肠溶片剂及其制备方法
WO2014125504A2 (en) * 2013-02-18 2014-08-21 Hetero Research Foundation Pharmaceutical compositions of febuxostat
CN105579037A (zh) * 2013-05-31 2016-05-11 武田制药美国有限公司 用黄嘌呤氧化酶抑制剂治疗的方法和含黄嘌呤氧化酶抑制剂的组合物
EP2881116A1 (en) * 2013-12-05 2015-06-10 Ranbaxy Laboratories Limited Febuxostat composition
MX2017013489A (es) * 2015-04-20 2018-05-22 Twi Biotechnology Inc Formulaciones que contienen diacereina y metodos para la reduccion de los niveles en sangre de acido urico usando los mismos.
TWI684465B (zh) * 2015-04-22 2020-02-11 安成生物科技股份有限公司 含雙醋瑞因之製劑及使用其於降低尿酸血中濃度的方法
US20180344749A1 (en) * 2015-12-10 2018-12-06 Cogwellin, LLC Controlled release formulations of saliclate-releasing actives
CN106279024B (zh) * 2016-07-19 2018-09-14 华南理工大学 一种黄嘌呤氧化还原酶抑制剂及其制备方法与应用
CN106146419A (zh) * 2016-08-01 2016-11-23 沈阳药科大学 黄嘌呤氧化酶抑制剂
US20190374515A1 (en) * 2016-11-28 2019-12-12 Teijin Pharma Limited Therapeutic drug or prophylactic drug for diabetic nephropathy
CN110214008A (zh) * 2017-06-14 2019-09-06 江苏恒瑞医药股份有限公司 一种非布司他控释组合物及其制备方法
CN109721586B (zh) * 2017-10-27 2021-03-02 中国医科大学 一种5-苄基-3-吡啶基-1h-1,2,4-三唑类化合物及其制备方法和用途
CN108484494B (zh) * 2018-06-15 2021-07-30 沈阳药科大学 2-氧代-1,2-二氢吡啶-4-甲酸类化合物
CN108938591A (zh) * 2018-08-21 2018-12-07 天津双硕医药科技有限公司 一种含有非布司他的固体药物组合物
CN109157654B (zh) * 2018-11-06 2021-12-07 苏州大学 Tmx1的用途
CN111662239B (zh) * 2019-03-06 2023-07-28 中国医学科学院药物研究所 1,2,4-三唑类化合物及其制法和药物用途
US20220354855A1 (en) * 2019-10-09 2022-11-10 Mayo Foundation For Medical Education And Research Treatment for gastrointestinal disorders
CN113354616B (zh) * 2020-03-05 2024-03-26 中国医学科学院药物研究所 二芳基-1,2,4-三唑类化合物及其制法和药物用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0513379T3 (da) 1990-11-30 1996-09-30 Teijin Ltd 2-Arylthiazolderivater og farmaceutisk præparat indeholdende sådanne
AU703609B2 (en) 1995-04-07 1999-03-25 Teijin Limited Protective agent for organ or tissue
US6322819B1 (en) * 1998-10-21 2001-11-27 Shire Laboratories, Inc. Oral pulsed dose drug delivery system
JP4613275B2 (ja) 1998-11-02 2011-01-12 エラン ファーマ インターナショナル，リミティド 多粒子改質放出組成物
ECSP993280A (es) 1999-12-17 2001-07-27 Polimorfos de acido 2- (3- ciano -4 -isobutiloxi fenil) -4 -metil -5-tiazol carboxilico y metodo de produccion de los mismos
RU2219957C2 (ru) * 2001-11-19 2003-12-27 Пихлак Андрей Эдуардович Способ лечения подагры с помощью плазмосорбции
SI21301A (sl) 2002-09-11 2004-04-30 LEK farmacevtska družba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
CN1713897B (zh) 2002-10-16 2012-07-04 武田药品工业株式会社 控释制剂
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
FR2878159B1 (fr) 2004-11-24 2008-10-17 Flamel Technologies Sa Medicament oral a liberation modifiee d'au moins un principe actif sous forme multimicrocapsulaire
EP1854463A4 (en) * 2005-03-03 2011-03-23 Takeda Pharmaceutical COMPOSITION WITH CONTROLLED RELEASE
WO2006121995A2 (en) 2005-05-09 2006-11-16 Tap Pharmaceutical Products, Inc. Methods for treating nephrolithiasis
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007073702A2 (es) * 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
KR20160031040A (ko) * 2006-11-13 2016-03-21 다케다 파마슈티칼스 유에스에이, 인코포레이티드 크산틴 옥시도리덕타아제 억제제를 사용하여 신장 기능을 보존하는 방법
US8110226B2 (en) 2007-07-20 2012-02-07 Mylan Pharmaceuticals Inc. Drug formulations having inert sealed cores
BRPI0913129A2 (pt) * 2008-05-22 2016-01-05 Bristol Myers Squibb Co método para tratamento de hiperuricemia empregando um inibidor de sglt2 e composição contendo o mesmo
CN101716132B (zh) * 2008-10-09 2012-01-11 北京方策方程医药科技有限公司 非布索坦肠溶制剂
CN101474175B (zh) 2009-01-20 2014-07-02 重庆医药工业研究院有限责任公司 一种高生物利用度非布司他口服固体制剂及其制备方法
CN101658505A (zh) * 2009-09-29 2010-03-03 北京华禧联合科技发展有限公司 非布索坦的缓释制剂及其制备方法
CN101711743B (zh) 2009-12-04 2011-08-24 山东淄博新达制药有限公司 非布索坦干混悬剂及其制备方法
CN101711751A (zh) 2009-12-04 2010-05-26 山东淄博新达制药有限公司 非布索坦分散片及其制备方法
CN101773498B (zh) 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
UY33468A (es) 2010-06-25 2012-01-31 Teijin Pharma Ltd Agente terapeutico de liberacion sostenida para la hipertension y la disfunción renal
NZ605562A (en) 2010-07-09 2013-11-29 Teijin Pharma Ltd Deuterated benzylbenzene derivatives and methods of use

Also Published As

Publication number Publication date
US20110311620A1 (en) 2011-12-22
JP2016104774A (ja) 2016-06-09
HK1187371A1 (zh) 2014-04-04
AU2011268445B2 (en) 2015-05-07
JP5865904B2 (ja) 2016-02-17
EP2582812B1 (en) 2018-01-24
RU2013101767A (ru) 2014-07-27
MX2012014836A (es) 2013-05-01
NZ604646A (en) 2014-11-28
BR112012032033A2 (pt) 2017-10-31
AU2011268445A1 (en) 2013-01-10
KR20130129826A (ko) 2013-11-29
AU2011268445B9 (en) 2015-05-07
EP2582812A1 (en) 2013-04-24
ECSP13012394A (es) 2013-04-30
JP2013528651A (ja) 2013-07-11
TW201202249A (en) 2012-01-16
CL2012003548A1 (es) 2013-09-06
CN103210084B (zh) 2016-04-20
UA112632C2 (uk) 2016-10-10
AU2015204313A1 (en) 2015-08-06
US9248119B2 (en) 2016-02-02
JO3450B1 (ar) 2020-07-05
KR101872189B1 (ko) 2018-06-29
RU2602188C2 (ru) 2016-11-10
CO6650415A2 (es) 2013-04-15
PE20170306A1 (es) 2017-05-06
SG186301A1 (en) 2013-02-28
IL264441A (en) 2019-02-28
CN103210084A (zh) 2013-07-17
WO2011159745A1 (en) 2011-12-22
IL223455B (en) 2019-01-31
MX361138B (es) 2018-11-28
PE20130574A1 (es) 2013-06-01
ZA201209386B (en) 2016-08-31
CA2801930A1 (en) 2011-12-22
AU2015204313B2 (en) 2017-11-16
MY167126A (en) 2018-08-13
US20160317505A1 (en) 2016-11-03
EP2582812A4 (en) 2013-12-04
ES2669184T3 (es) 2018-05-24
US9937157B2 (en) 2018-04-10

Similar Documents

Publication Publication Date Title
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
MX2019010602A (es) Inhibidores de cdk.
JO3025B1 (ar) الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
WO2012142498A3 (en) Mif inhibitors and their uses
IN2012DN03883A (es)
MX355728B (es) Inhibidores de cinasas.
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
TN2011000673A1 (en) Bace inhibitors
UA110197C2 (ru) Соединения, эффективные как ингибиторы для ксантиноксидазы, процесса получения таких соединений и фармацевтической композиции, содержащей терапевтически эффективное количество таких соединений.
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
IN2013MN00501A (es)
PH12014502588A1 (en) Catechol o-methyltransferase activity inhibiting compounds
WO2013003298A3 (en) Inhibitors of pde10
EA201290822A1 (ru) Триазолоны в качестве ингибиторов синтазы жирных кислот
MX2009005829A (es) Polialquileniminas hidrofobicamente modificadas para usarse como inhibidores de transferencia de colorante.
PH12014501032A1 (en) 2-thiopyrimidinones
EA201270280A1 (ru) Соединения пиримидина в качестве ингибиторов при лечении туберкулеза
IN2012DN00539A (es)
IN2014DN08443A (es)
MX2012001875A (es) Proceso para la preparación de inhibidores de la catepsina s.
UA38064U (ru) Применение производных 2-оксоиндолин-3-глиоксиловой кислоты как средств ноотропного действия
UA96060C2 (ru) Применение липофлавона как средства фригопротекторного действия
UA41922U (ru) Применение альтана как вещества с противолучевыми свойствами